BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.
BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option. ZYESAMI® (aviptadil) is authorized for the treatment of acute respiratory distress syndrome, including in patients with critical COVID-19–related respiratory failure, representing the company’s expansion into critical care medicine.
In addition to its marketed products, BioXcel maintains a diversified pipeline of clinical and preclinical programs targeting neuropsychiatric and immuno-oncology indications. The company collaborates with academic institutions and strategic partners to further validate its AI-identified assets and explore new indications, underpinning its strategy to deliver differentiated treatments across multiple therapeutic areas.
Founded in 2017 and headquartered in New Haven, Connecticut, BioXcel Therapeutics completed its public listing in 2019. The company currently serves the U.S. market and is evaluating opportunities for global expansion. Under the leadership of President and CEO Vimal Mehta, M.D., Ph.D., BioXcel is focused on growing its commercial footprint and advancing its AI-enabled pipeline toward key regulatory milestones.
AI Generated. May Contain Errors.
Free BTAI Stock Alerts